Mulberrofuran G

Name: Mulberrofuran G
Brand: MedChemExpress
SKU: HY-N3239
Rating: 4.5 (0 reviews)

製品番号: HY-N3239 純度: 97.86%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Mulberrofuran G is a NOX inhibitor (IC₅₀: 6.9 μM) and tyrosinase inhibitor. Mulberrofuran G exhibits anti-inflammatory, antioxidant, antiviral, antitumor, and neuroprotective effects. Mulberrofuran G can be used in the research of tumors, nervous system diseases, and other conditions.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Mulberrofuran G 構造式

CAS 番号 : 87085-00-5

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 804	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 804	在庫あり	Estimated Time of Arrival: December 31
Solid
1 mg	$270	在庫あり	Estimated Time of Arrival: December 31
5 mg	$650	在庫あり	Estimated Time of Arrival: December 31
10 mg		お問い合わせ
50 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

NADPH Oxidase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

NOX1 NOX2 NOX4 NOX5 DUOX1

JAK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

JAK1 JAK2 JAK3 Tyk2 JAK

STAT アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

STAT3 STAT5 STAT6 STAT1

Caspase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

PARP アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[2]^[4]

NOX4

JAK2

STAT3

Caspase 3

Caspase-9

Cellular Effect

Cell Line	Type	Value	Description	References
Hep 3B2	IC₅₀	>30 3 Compound: 6	Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay	[PMID: 19072214]
Hep 3B2	IC₅₀	> 30 3 Compound: 6	Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay	[PMID: 19072214]
Hep 3B2	IC₅₀	2.6 3 Compound: 6	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	[PMID: 19072214]
Hep 3B2	IC₅₀	2.6 3 Compound: 6	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	[PMID: 19072214]
Hep 3B2	IC₅₀	2.6 3 Compound: 6	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	[PMID: 19072214]
Hep 3B2	IC₅₀	28.6 3 Compound: 6	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	[PMID: 19072214]
Hep 3B2	IC₅₀	28.6 3 Compound: 6	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	[PMID: 19072214]
Hep 3B2	IC₅₀	28.6 3 Compound: 6	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	[PMID: 19072214]
Hep 3B2	IC₅₀	> 30 3 Compound: 6	Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay	[PMID: 19072214]
Platelet	IC₅₀	8.9 × 10^-5 41 Compound: Mulberrofuran G	Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets	[PMID: 3097265]
Platelet	IC₅₀	1.07 x 10^-5 41 Compound: Mulberrofuran G	Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets	[PMID: 3097265]
Platelet	IC₅₀	1.07 × 10^-5 41 Compound: Mulberrofuran G	Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets	[PMID: 3097265]
Platelet	IC₅₀	3.47 x 10^-5 41 Compound: Mulberrofuran G	Inhibition of thromboxane B2 formation in Wistar King platelets Inhibition of thromboxane B2 formation in Wistar King platelets	[PMID: 3097265]
Platelet	IC₅₀	3.47 × 10^-5 41 Compound: Mulberrofuran G	Inhibition of thromboxane B2 formation in Wistar King platelets Inhibition of thromboxane B2 formation in Wistar King platelets	[PMID: 3097265]
Platelet	IC₅₀	8.9 x 10^-5 41 Compound: Mulberrofuran G	Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets	[PMID: 3097265]

体外実験

Mulberrofuran G (0.89-909.42 μM) inhibits HBV DNA replication in HepG 2.2.15 cells with an IC₅₀ of 3.99 μM, and exhibits cytotoxicity to HepG 2.2.15 cells with a CC₅₀ of 8.04 μM^[1].
Mulberrofuran G (1-100 μM; 24 h) significantly suppresses cell proliferation, migration, and invasion in A549 and NCI-H226 cells, with the mechanism involving the inhibition of the JAK2/STAT3 pathway^[2].
Mulberrofuran G (0-3 μM; 24 h) potently inhibits the infection of SARS-CoV-2 (βCoV/Korea/KCDC03/2020) in Vero cells, with an IC₅₀ of 1.55 μM^[3].
Mulberrofuran G (0.016-2 μM; 4-40 h) enhances cell viability, suppresses ROS production and apoptotic signals, and alleviates ER stress in oxygen-glucose deprivation/reoxygenation-treated SH-SY5Y cells. The mechanism is associated with the inhibition of NOX4^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	A549 cells and NCIH226 cells
Concentration:	1, 5, 10 and 100 μM
Incubation Time:	24 h
Result:	Significantly inhibited the proliferation of lung cancer cells with IC₅₀ values of 22.5 μM and 30.6 μM for A549 cells and NCIH226 cells, respectively.

Western Blot Analysis^[4]

Cell Line:	SH-SY5Y cells treated oxygen-glucose deprivation/reoxygenation (OGD/R)
Concentration:	0.08, 0.4, and 2 μM
Incubation Time:	40 h
Result:	Inhibited the levels of cleaved caspase-9, caspase-3, and PARP.

体内実験

Mulberrofuran G (0.2-5 mg/kg; intraperitoneal injection; single dose; 30 min before operation) exerts a protective effect in a rat model of middle cerebral artery occlusion/reperfusion^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (230-240 g) with middle cerebral artery occlusion/reperfusion (MCAO/R)^[4]
Dosage:	0.2, 1 and 5 mg/kg
Administration:	Intraperitoneal injection; single dose; 30 min before operation
Result:	Significantly decreased the infarct volume in a dose-dependent manner, with the infarct volumes of 0.2, 1, and 5 mg/kg groups being 39.0%, 26.0%, and 19.0% respectively, compared to 51.2% in the vehicle group. Downregulated the protein expression of NOX4, GRP78/BiP, p-IRE1α, XBP1, and CHOP in the ischemic brain tissue.

分子量

562.57

分子式

C₃₄H₂₆O₈

CAS 番号

87085-00-5

Appearance

Solid

Color

White to off-white

SMILES

OC1=C(C=CC(O)=C1)[C@]23[C@]4([H])[C@](C=C(C)C[C@@]4([H])C5=C(C=C(O)C=C5)O3)([H])C6=C(O)C=C(C7=CC8=C(C=C(O)C=C8)O7)C=C6O2

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (88.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7776 mL	8.8878 mL	17.7756 mL
5 mM	0.3555 mL	1.7776 mL	3.5551 mL
10 mM	0.1778 mL	0.8888 mL	1.7776 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 97.86%

Select Batch:

データシート (280 KB) SDS (393 KB)

COA (251 KB) HNMR (321 KB) LCMS (86 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Geng CA, et al. Mulberrofuran G and isomulberrofuran G from Morus alba L.: anti-hepatitis B virus activity and mass spectrometric fragmentation. J Agric Food Chem. 2012;60(33):8197-8202. [Content Brief]

[2]. HaiYuanBo G, et al. Mulberrofuran G inhibits proliferation and migration by inactivating JAK2/STAT3 signaling in lung cancer cells. Bangladesh Journal of Pharmacology, 2021, 16(4): 134-140.

[3]. Kim YS, et al. Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor. Nutrients. 2022 Oct 7;14(19):4170. [Content Brief]

[4]. Hong S, et al. Mulberrofuran G Protects Ischemic Injury-induced Cell Death via Inhibition of NOX4-mediated ROS Generation and ER Stress. Phytother Res. 2017;31(2):321-329. [Content Brief]

[5]. Koirala P, et al. Structure⁻Activity Relationship of the Tyrosinase Inhibitors Kuwanon G, Mulberrofuran G, and Albanol B from Morus Species: A Kinetics and Molecular Docking Study. Molecules. 2018 Jun 11;23(6):1413. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7776 mL	8.8878 mL	17.7756 mL	44.4389 mL
	5 mM	0.3555 mL	1.7776 mL	3.5551 mL	8.8878 mL
	10 mM	0.1778 mL	0.8888 mL	1.7776 mL	4.4439 mL
	15 mM	0.1185 mL	0.5925 mL	1.1850 mL	2.9626 mL
	20 mM	0.0889 mL	0.4444 mL	0.8888 mL	2.2219 mL
	25 mM	0.0711 mL	0.3555 mL	0.7110 mL	1.7776 mL
	30 mM	0.0593 mL	0.2963 mL	0.5925 mL	1.4813 mL
	40 mM	0.0444 mL	0.2222 mL	0.4444 mL	1.1110 mL
	50 mM	0.0356 mL	0.1778 mL	0.3555 mL	0.8888 mL
	60 mM	0.0296 mL	0.1481 mL	0.2963 mL	0.7406 mL
	80 mM	0.0222 mL	0.1111 mL	0.2222 mL	0.5555 mL

Mulberrofuran G Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

Mulberrofuran G

カスタマーレビュー

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NADPH Oxidase アイソフォーム固有の製品をすべて表示:

JAK アイソフォーム固有の製品をすべて表示:

STAT アイソフォーム固有の製品をすべて表示:

Caspase アイソフォーム固有の製品をすべて表示:

PARP アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mulberrofuran G Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Mulberrofuran G

カスタマーレビュー

Mulberrofuran G 関連抗体

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NADPH Oxidase アイソフォーム固有の製品をすべて表示:

JAK アイソフォーム固有の製品をすべて表示:

STAT アイソフォーム固有の製品をすべて表示:

Caspase アイソフォーム固有の製品をすべて表示:

PARP アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Mulberrofuran G 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mulberrofuran G Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report